MA46860A - Inhibiteurs de magl - Google Patents

Inhibiteurs de magl

Info

Publication number: MA46860A
Authority: MA; Morocco
Prior art keywords: magl inhibitors; magl; inhibitors
Prior art date: 2016-11-16

Application number

MA046860A

Other languages

English (en)

Inventor

Daniel J Buzard

Cheryl A Grice

Donald L Hertzog

Nicole S White

Original Assignee

Abide Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-16

Filing date

2017-11-15

Publication date

2019-09-25

2017-11-15 Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc

2019-09-25 Publication of MA46860A publication Critical patent/MA46860A/fr

Links

102100029814 Monoglyceride lipase Human genes 0.000 title 1
101710116393 Monoglyceride lipase Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA046860A 2016-11-16 2017-11-15 Inhibiteurs de magl MA46860A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662423095P	2016-11-16	2016-11-16

Publications (1)

Publication Number	Publication Date
MA46860A true MA46860A (fr)	2019-09-25

Family

ID=62107273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046860A MA46860A (fr)	2016-11-16	2017-11-15	Inhibiteurs de magl

Country Status (27)

Country	Link
US (1)	US9981930B1 (fr)
EP (1)	EP3541822B1 (fr)
JP (1)	JP6987859B2 (fr)
KR (1)	KR20190077087A (fr)
CN (1)	CN110248947B (fr)
AR (1)	AR110088A1 (fr)
AU (1)	AU2017361250A1 (fr)
BR (1)	BR112019009991A2 (fr)
CA (1)	CA3043612A1 (fr)
CL (1)	CL2019001335A1 (fr)
CO (1)	CO2019005038A2 (fr)
CR (1)	CR20190243A (fr)
DO (1)	DOP2019000121A (fr)
EA (1)	EA201991074A1 (fr)
EC (1)	ECSP19035377A (fr)
ES (1)	ES2908632T3 (fr)
IL (1)	IL266550A (fr)
JO (1)	JOP20190105A1 (fr)
MA (1)	MA46860A (fr)
MX (1)	MX2019005771A (fr)
NI (1)	NI201900050A (fr)
PE (1)	PE20191146A1 (fr)
PH (1)	PH12019501102A1 (fr)
RU (1)	RU2019116514A (fr)
TN (1)	TN2019000150A1 (fr)
TW (1)	TW201831458A (fr)
WO (1)	WO2018093946A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2793148T3 (es)	2012-01-06	2020-11-13	Lundbeck La Jolla Research Center Inc	Compuestos de carbamato y métodos para fabricarlos y usarlos
CA2984480A1 (fr)	2015-05-11	2016-11-17	Abide Therapeutics, Inc.	Procedes de traitement de l'inflammation ou de la douleur neuropathique
US10899737B2 (en)	2016-09-19	2021-01-26	Lundbeck La Jolla Research Center, Inc.	Piperazine carbamates and methods of making and using same
AU2017361254B2 (en)	2016-11-16	2021-09-23	H. Lundbeck A/S.	Pharmaceutical formulations
EP3541807B1 (fr)	2016-11-16	2021-09-29	H. Lundbeck A/S	Une forme cristalline d'un inhibiteur de magl
JOP20190106A1 (ar) *	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar)	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3072923A1 (fr)	2017-08-29	2019-03-07	Lundbeck La Jolla Research Center, Inc.	Composes spirocycliques et procedes de preparation et d'utilisation de ceux-ci
GEP20227373B (en) *	2017-11-02	2022-04-25	Aicuris Gmbh & Co Kg	Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
CR20200545A (es)	2018-05-15	2020-12-17	Lundbeck La Jolla Research Center Inc	Inhibidores magl
CN115427403A (zh) *	2020-04-21	2022-12-02	H.隆德贝克有限公司	单酰基甘油脂肪酶抑制剂的合成
TWI904281B (zh)	2020-11-13	2025-11-11	丹麥商Ｈ朗德貝克公司	Magl抑制劑
CA3242372A1 (fr)	2021-12-29	2023-07-06	Psy Therapeutics, Inc.	Inhibition de la monoacylglycerol lipase (magl)
AU2023264787A1 (en)	2022-05-04	2024-10-31	H. Lundbeck A/S	Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1593586A (fr)	1967-10-17	1970-06-01
JPS6183073A (ja)	1984-10-01	1986-04-26	Oki Electric Ind Co Ltd	印字装置の用紙送り方法
WO1989011794A1 (fr)	1988-06-07	1989-12-14	Rikagaku Kenkyusho	Inhibiteur de la croissance de plantes
DE69211015T2 (de)	1991-11-27	1997-01-09	Du Pont	Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
DE69408873T2 (de)	1993-12-22	1998-07-09	Shell Int Research	Verfahren zur herstellung von carbamaten
EP0863879A1 (fr)	1995-11-15	1998-09-16	Zeneca Limited	Composes herbicides a base de pyrazole substitue
AU3440597A (en)	1996-07-02	1998-01-21	Novartis Ag	N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru)	1998-03-25	2001-05-20	Фокин Александр Васильевич	Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
ATE432993T1 (de)	1999-10-04	2009-06-15	Univ New Jersey Med	Tar rna bindende peptide
EP1201298A1 (fr)	2000-10-24	2002-05-02	Urea Casale S.A.	Dispositif pour la condensation de carbamate
DE10348022A1 (de)	2003-10-15	2005-05-25	Imtm Gmbh	Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr)	2003-12-23	2006-02-03	Sanofi Synthelabo	Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (fr)	2003-12-31	2005-07-14	Council Of Scientific & Industrial Research	Procede de preparation de carbamates
KR20070026382A (ko)	2004-02-18	2007-03-08	아스트라제네카 아베	아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
AR048528A1 (es) *	2004-04-07	2006-05-03	Millennium Pharm Inc	Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
CA2589877A1 (fr)	2004-12-23	2006-06-29	F. Hoffmann-La Roche Ag	Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
RS56194B1 (sr)	2004-12-30	2017-11-30	Janssen Pharmaceutica Nv	Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
JP2009523729A (ja)	2006-01-13	2009-06-25	ピーティーシーセラピューティクス，インコーポレーテッド	Ｃ型肝炎の治療方法
US20100234351A1 (en)	2006-02-23	2010-09-16	Takeda Pharmaceutical Company Limited	Fused nitrogen-comprising heterocyclic compound
MX2009006706A (es)	2006-12-22	2009-07-02	Astex Therapeutics Ltd	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CN101711154A (zh)	2007-02-26	2010-05-19	科森生物科学公司	氨基甲酸酯化合物
JP2008239616A (ja) *	2007-02-28	2008-10-09	Iyaku Bunshi Sekkei Kenkyusho:Kk	Ｈｄｌ上昇剤
US8188098B2 (en)	2008-05-19	2012-05-29	Hoffmann-La Roche Inc.	GPR119 receptor agonists
EP2328897A1 (fr)	2008-07-16	2011-06-08	Schering Corporation	Dérivés hétérocycliques bicycliques et leur utilisation comme modulateurs de gpcr
EP2373315A4 (fr)	2008-11-14	2012-06-27	Scripps Research Inst	Procédé et composition se rapportant au ciblage de la mono-acylglycérol lipase
CA2755806A1 (fr)	2009-03-23	2010-09-30	Msd K.K.	Nouveaux derives d'aminopyridine presentant une action inhibitrice selective de l'aurora a
UA107791C2 (en)	2009-05-05	2015-02-25	Dow Agrosciences Llc	Pesticidal compositions
ES2433235T3 (es)	2009-11-03	2013-12-10	Bayer Intellectual Property Gmbh	Fluorouretanos como aditivos en una formulación de fotopolímero
FR2960875B1 (fr)	2010-06-04	2012-12-28	Sanofi Aventis	Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
ES2793148T3 (es)	2012-01-06	2020-11-13	Lundbeck La Jolla Research Center Inc	Compuestos de carbamato y métodos para fabricarlos y usarlos
KR101893112B1 (ko)	2012-01-06	2018-08-30	아지오스 파마슈티컬스 아이엔씨.	치료학적으로 활성인 화합물 및 이의 이용 방법
WO2013142307A1 (fr) *	2012-03-19	2013-09-26	Abide Therapeutics	Composés carbamates et leur procédé de fabrication et d'utilisation
US9551036B2 (en)	2013-02-25	2017-01-24	Whitehead Institute For Biomedical Research	Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja)	2013-07-03	2020-02-14	ルンドベックラホーヤリサーチセンター，インク．	ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
CA2979537C (fr)	2015-03-18	2023-08-29	Abide Therapeutics, Inc.	Carbamates de piperazine et procedes de preparation et d'utilisation de ceux-ci
CA2984480A1 (fr) *	2015-05-11	2016-11-17	Abide Therapeutics, Inc.	Procedes de traitement de l'inflammation ou de la douleur neuropathique
US10463753B2 (en) *	2016-02-19	2019-11-05	Lundbeck La Jolla Research Center, Inc.	Radiolabeled monoacylglycerol lipase occupancy probe
ES2861648T3 (es) *	2016-05-12	2021-10-06	Lundbeck La Jolla Research Center Inc	Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190107A1 (ar) *	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) *	2017-05-23	2019-11-18	Lundbeck La Jolla Research Center Inc	مثبطات بيرازول magl

2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja not_active Expired - Fee Related
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh not_active Expired - Fee Related
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko not_active Withdrawn
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-15 CA CA3043612A patent/CA3043612A1/fr not_active Abandoned
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/fr active Active
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/fr not_active Ceased
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown

Also Published As

Publication number	Publication date
IL266550A (en)	2019-07-31
JOP20190105A1 (ar)	2019-05-09
JP6987859B2 (ja)	2022-01-05
AR110088A1 (es)	2019-02-20
PE20191146A1 (es)	2019-09-02
EA201991074A1 (ru)	2019-12-30
EP3541822A4 (fr)	2020-04-29
CN110248947B (zh)	2022-04-01
PH12019501102A1 (en)	2019-08-19
CR20190243A (es)	2019-06-26
JP2020502047A (ja)	2020-01-23
CA3043612A1 (fr)	2018-05-24
WO2018093946A1 (fr)	2018-05-24
US20180134675A1 (en)	2018-05-17
KR20190077087A (ko)	2019-07-02
DOP2019000121A (es)	2019-09-30
CL2019001335A1 (es)	2019-10-04
RU2019116514A (ru)	2020-12-17
TW201831458A (zh)	2018-09-01
NI201900050A (es)	2019-10-30
MX2019005771A (es)	2019-12-05
US9981930B1 (en)	2018-05-29
ES2908632T3 (es)	2022-05-03
CO2019005038A2 (es)	2019-05-31
TN2019000150A1 (en)	2020-10-05
CN110248947A (zh)	2019-09-17
EP3541822B1 (fr)	2022-01-19
BR112019009991A2 (pt)	2019-08-27
AU2017361250A1 (en)	2019-05-30
EP3541822A1 (fr)	2019-09-25
ECSP19035377A (es)	2019-05-31

Publication	Publication Date	Title
EP3541932A4 (fr)	2021-03-03	Inhibiteurs de crispr-cas9
MA46855A (fr)	2021-05-19	Inhibiteurs de magl
MA46857A (fr)	2019-09-25	Inhibiteurs de magl
EP3793547A4 (fr)	2021-11-17	Inhibiteurs de magl
DK3405050T3 (da)	2020-06-02	Børnesikret snusbeholder
EP3541822A4 (fr)	2020-04-29	Inhibiteurs de magl
DK3442972T3 (da)	2020-04-27	Bromdomænehæmmere
LT3303334T (lt)	2021-07-12	Tirozinkinazės inhibitoriai
EP3283077A4 (fr)	2019-01-23	Inhibiteurs de bromodomaine
EP3313828A4 (fr)	2019-01-09	Inhibiteurs de métallo-bêta-lactamases
DK3436823T3 (da)	2021-04-26	Antigen-array
DK3335532T3 (da)	2019-10-14	Tandharve
DK3402792T3 (da)	2021-11-15	Quinolin-2-on-derivater
EP3394068A4 (fr)	2019-07-03	Inhibiteurs de tdo2
MA50406A (fr)	2020-08-26	Inhibiteurs pyrazole de magl
DK3445708T3 (da)	2021-06-07	Stigbøjle
MA43367A (fr)	2018-10-10	Inhibiteurs de métallo-bêta-lactamases
DK3452590T3 (da)	2022-01-24	Plademagnet
MA46889A (fr)	2019-10-02	Inhibiteurs de gsk-3
MA46280A (fr)	2019-07-31	Inhibiteurs de la dopamine-b-hydroxylase
DK3481826T3 (da)	2022-01-10	Tyrosinkinaseinhibitorer
DE112017006386A5 (de)	2019-08-29	Schraubarbeitszylinder
DK3323708T3 (da)	2019-06-24	Bovfender
EP3528810A4 (fr)	2020-06-17	Inhibiteur de bromodomaines
DK3452587T3 (da)	2021-10-11	Penicillin-g-acylaser